AU2011279555B2 - Diagnostic for colorectal cancer - Google Patents

Diagnostic for colorectal cancer Download PDF

Info

Publication number
AU2011279555B2
AU2011279555B2 AU2011279555A AU2011279555A AU2011279555B2 AU 2011279555 B2 AU2011279555 B2 AU 2011279555B2 AU 2011279555 A AU2011279555 A AU 2011279555A AU 2011279555 A AU2011279555 A AU 2011279555A AU 2011279555 B2 AU2011279555 B2 AU 2011279555B2
Authority
AU
Australia
Prior art keywords
biomarkers
colorectal cancer
level
m2pk
igfbp2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2011279555A
Other languages
English (en)
Other versions
AU2011279555A1 (en
Inventor
Antony Wilks Burgess
Leah Jane Cosgrove
Edouard Collins Nice
Bruce Tabor
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vision Tech Bio Pty Ltd
Original Assignee
Vision Tech Bio Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2010903140A external-priority patent/AU2010903140A0/en
Application filed by Vision Tech Bio Pty Ltd filed Critical Vision Tech Bio Pty Ltd
Priority to AU2011279555A priority Critical patent/AU2011279555B2/en
Publication of AU2011279555A1 publication Critical patent/AU2011279555A1/en
Application granted granted Critical
Publication of AU2011279555B2 publication Critical patent/AU2011279555B2/en
Assigned to VISION TECH BIO PTY LTD reassignment VISION TECH BIO PTY LTD Request for Assignment Assignors: COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57419—Specifically defined cancers of colon
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
AU2011279555A 2010-07-14 2011-07-14 Diagnostic for colorectal cancer Active AU2011279555B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2011279555A AU2011279555B2 (en) 2010-07-14 2011-07-14 Diagnostic for colorectal cancer

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
AU2010903140A AU2010903140A0 (en) 2010-07-14 Diagnostic for colorectal cancer
AU2010903140 2010-07-14
AU2011279555A AU2011279555B2 (en) 2010-07-14 2011-07-14 Diagnostic for colorectal cancer
PCT/AU2011/000895 WO2012006681A1 (en) 2010-07-14 2011-07-14 Diagnostic for colorectal cancer

Publications (2)

Publication Number Publication Date
AU2011279555A1 AU2011279555A1 (en) 2013-01-31
AU2011279555B2 true AU2011279555B2 (en) 2016-10-20

Family

ID=45468816

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2011279555A Active AU2011279555B2 (en) 2010-07-14 2011-07-14 Diagnostic for colorectal cancer

Country Status (13)

Country Link
US (2) US20130345322A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (2) EP2829881B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JP6061344B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (2) CN103140760B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU2011279555B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BR112013000745B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK2829881T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2653646T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IN (1) IN2013CN01129A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (1) NO2829881T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (1) PT2829881T (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RU (1) RU2013103995A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO2012006681A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN2013CN01129A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2010-07-14 2015-07-31 Commw Scient Ind Res Org
US9141756B1 (en) 2010-07-20 2015-09-22 University Of Southern California Multi-scale complex systems transdisciplinary analysis of response to therapy
EP2671082B1 (en) 2011-02-02 2020-01-15 Amgen Inc. Methods and compositons relating to inhibition of igf-1r
HUE042708T2 (hu) * 2012-08-09 2019-07-29 Inst Nat Sante Rech Med Szívelégtelenség diagnosztika
GB201218341D0 (en) * 2012-10-12 2012-11-28 Orign Sciences Ltd Diagnostic method
JP2017520775A (ja) * 2014-03-28 2017-07-27 アプライド プロテオミクス，インク． 結腸直腸腫瘍を検出するためのタンパク質バイオマーカープロファイル
SG11201700284UA (en) * 2014-07-18 2017-02-27 Sanofi Sa Method for predicting the outcome of a treatment with aflibercept of a patient suspected to suffer from a cancer
CN106191215B (zh) * 2015-04-29 2020-03-24 中国科学院上海生命科学研究院 肌肉萎缩相关的蛋白质分子标记Dkk-3的筛选及其应用
CN107847564B (zh) * 2015-05-12 2021-11-09 远东超级实验室有限公司 鉴定对肿瘤具有直接抑制作用的干扰素的方法及其用途
CN105219844B (zh) * 2015-06-08 2018-12-14 华夏京都医疗投资管理有限公司 一种筛查十一种疾病的基因标志物组合、试剂盒以及疾病风险预测模型
CN105021828B (zh) * 2015-07-20 2017-07-28 上海交通大学医学院附属新华医院 通过检测三期结直肠肿瘤患者血清预测肿瘤患者预后
CN105567846A (zh) * 2016-02-14 2016-05-11 上海交通大学医学院附属仁济医院 检测粪便中细菌dna的试剂盒及其在大肠癌诊断中的应用
JP6984862B2 (ja) * 2017-03-15 2021-12-22 国立大学法人金沢大学 血中ケモカインをマーカーとして用いた大腸癌の検出
CN107164535A (zh) * 2017-07-07 2017-09-15 沈阳宁沪科技有限公司 一种无创高通量甲基化结肠癌诊断、研究和治疗方法
CN110540588B (zh) * 2018-05-28 2022-08-23 香港中文大学 一种基于肿瘤干细胞标志物EpCAM的抗原表位多肽及其应用
CN108957014A (zh) * 2018-09-27 2018-12-07 郑州大学第附属医院 结直肠癌血清标志物、表达评估方法、试剂盒及应用
JP2022505676A (ja) * 2018-10-23 2022-01-14 ブラックソーン セラピューティクス インコーポレイテッド 患者のスクリーニング、診断、及び層別化のためのシステム及び方法
CN109504778B (zh) * 2019-01-11 2021-11-09 复旦大学附属中山医院 一种基于表观修饰的5hmC多分子标志物及结直肠癌早期诊断模型
CA3131729A1 (en) * 2019-03-01 2020-09-10 Advanced Marker Discovery S.l. Protein signature for the diagnosis of colorectal cancer and/or pre-cancerous stage thereof
JP7032764B2 (ja) * 2019-04-03 2022-03-09 京都府公立大学法人 大腸がんの検出方法
JP7300660B2 (ja) * 2019-04-03 2023-06-30 京都府公立大学法人 大腸がんの検出方法
WO2021097327A1 (en) * 2019-11-13 2021-05-20 University Of Virginia Patent Foundation Treatment of clostridium difficile infections
EP3835789A1 (en) 2019-12-13 2021-06-16 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Biomarker panel for diagnosing colorectal cancer
WO2022130597A1 (ja) * 2020-12-18 2022-06-23 国立大学法人東北大学 推定装置、推定方法、推定プログラム、生成装置、及び、推定システム
CN117355748A (zh) * 2021-04-20 2024-01-05 视觉技术生物有限公司 结直肠癌的生物标志物
CA3228665A1 (en) * 2021-08-11 2023-02-16 Trevor Lockett Method of detecting adenoma
WO2023128429A1 (ko) * 2021-12-31 2023-07-06 주식회사 이노제닉스 대장암 및 진행 선종의 선별 검사 방법 및 그 응용
WO2023128419A1 (ko) * 2021-12-31 2023-07-06 주식회사 이노제닉스 대장암 및 대장 용종 또는 진행 선종의 선별 방법 및 그 응용
CN114594259B (zh) * 2022-04-22 2022-09-13 北京易科拜德科技有限公司 一种新型的用于结直肠癌预后预测和诊断的模型及其应用
PL441319A1 (pl) * 2022-05-31 2023-12-04 Uniwersytet Medyczny Im. Piastów Śląskich We Wrocławiu Zestaw biomarkerów białkowych i sposób diagnostyki raka jelita grubego in vitro
CN119688988A (zh) * 2024-11-25 2025-03-25 中国医学科学院肿瘤医院 Timp1和foxp3作为诊断结直肠癌的生物标志物组合及其应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008079269A2 (en) * 2006-12-19 2008-07-03 Genego, Inc. Novel methods for functional analysis of high-throughput experimental data and gene groups identified therfrom
WO2008138522A1 (en) * 2007-05-10 2008-11-20 Roche Diagnostics Gmbh Use of timp-1 as a marker for colorectal cancer
WO2008144345A2 (en) * 2007-05-17 2008-11-27 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to insulin growth factor-1 receptor modulators
WO2009037572A2 (en) * 2007-06-04 2009-03-26 Diagnoplex Biomarker combinations for colorectal cancer
WO2010065567A2 (en) * 2008-12-01 2010-06-10 Lifespan Extension Llc Methods and compositions for altering health, wellbeing, and lifespan
WO2011090516A1 (en) * 2010-01-19 2011-07-28 Predictive Biosciences, Inc. Antibodies and methods of diagnosing diseases

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5925517A (en) 1993-11-12 1999-07-20 The Public Health Research Institute Of The City Of New York, Inc. Detectably labeled dual conformation oligonucleotide probes, assays and kits
JP2004198419A (ja) * 2002-12-13 2004-07-15 Bayer Healthcare Llc Ｔｉｍｐ１を用いた検出方法
US20050014165A1 (en) * 2003-07-18 2005-01-20 California Pacific Medical Center Biomarker panel for colorectal cancer
US20060094056A1 (en) * 2003-09-15 2006-05-04 Oklahoma Medical Research Foundation Method of using cytokine assays to diagnose treat, and evaluate inflammatory and autoimmune diseases
BRPI0401830A (pt) 2004-05-25 2006-01-17 Bentonit Uniao Nordeste Sa Processo de produção de pós granulados secos
JP5399900B2 (ja) * 2006-06-30 2014-01-29 メルク・シャープ・アンド・ドーム・コーポレーション Ｉｇｆｂｐ２インヒビター
WO2008073660A1 (en) 2006-11-09 2008-06-19 University Of Washington Molecules and methods for treatment and detection of cancer
JP2010517582A (ja) 2007-02-12 2010-05-27 ザ・ジョンズ・ホプキンス・ユニバーシティー 結腸癌の早期検出および予後診断の方法
SI2472264T1 (sl) * 2007-02-27 2016-06-30 SentoClone International AB Karolinska Institute Science Park Multipleksna detekcija tumorskih celic z uporabo plošč vezavnih sredstev na zunajcelične markerje
WO2008116178A2 (en) * 2007-03-21 2008-09-25 Vanderbilt University Systems and methods for diagnosis and prognosis of colorectal cancer
US20090017463A1 (en) * 2007-07-10 2009-01-15 Vanderbilt University Methods for predicting prostate cancer recurrence
EP2271775A4 (en) * 2008-04-08 2011-09-07 Nuclea Biomarkers Llc BIOMARKERGROUP FOR PREDICTING THE REPRESENTATION OF COLORECTAL CARCINOMA
US20100111969A1 (en) * 2008-10-31 2010-05-06 Apogenix Gmbh Il-4 receptor and il-13 as prognostic markers for colon and pancreas tumors
EP2370813A4 (en) * 2008-12-04 2012-05-23 Univ California MATERIALS AND METHODS FOR DIAGNOSIS AND PRESENTATION OF PROSTATE CANCER
US9354233B2 (en) * 2009-02-20 2016-05-31 The Regents Of The University Of California A+ biomarker assays
IN2013CN01129A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * 2010-07-14 2015-07-31 Commw Scient Ind Res Org

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008079269A2 (en) * 2006-12-19 2008-07-03 Genego, Inc. Novel methods for functional analysis of high-throughput experimental data and gene groups identified therfrom
WO2008138522A1 (en) * 2007-05-10 2008-11-20 Roche Diagnostics Gmbh Use of timp-1 as a marker for colorectal cancer
WO2008144345A2 (en) * 2007-05-17 2008-11-27 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to insulin growth factor-1 receptor modulators
WO2009037572A2 (en) * 2007-06-04 2009-03-26 Diagnoplex Biomarker combinations for colorectal cancer
WO2010065567A2 (en) * 2008-12-01 2010-06-10 Lifespan Extension Llc Methods and compositions for altering health, wellbeing, and lifespan
WO2011090516A1 (en) * 2010-01-19 2011-07-28 Predictive Biosciences, Inc. Antibodies and methods of diagnosing diseases

Also Published As

Publication number Publication date
CN105755112A (zh) 2016-07-13
PT2829881T (pt) 2017-11-29
RU2013103995A (ru) 2014-08-20
BR112013000745A2 (pt) 2016-05-24
BR112013000745B1 (pt) 2021-02-02
DK2829881T3 (en) 2017-12-04
US10877039B2 (en) 2020-12-29
EP2593795A4 (en) 2014-01-22
EP2593795A1 (en) 2013-05-22
JP2013533977A (ja) 2013-08-29
EP2829881A2 (en) 2015-01-28
EP2829881B1 (en) 2017-08-23
ES2653646T3 (es) 2018-02-08
WO2012006681A1 (en) 2012-01-19
CN105755112B (zh) 2019-06-07
CN103140760B (zh) 2016-01-27
CN103140760A (zh) 2013-06-05
US20130345322A1 (en) 2013-12-26
IN2013CN01129A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2015-07-31
US20170205414A1 (en) 2017-07-20
AU2011279555A1 (en) 2013-01-31
JP6061344B2 (ja) 2017-01-18
NO2829881T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2018-01-20
EP2829881A3 (en) 2015-05-13

Similar Documents

Publication Publication Date Title
AU2011279555B2 (en) Diagnostic for colorectal cancer
US9964542B2 (en) Bladder cancer detection composition, kit, and associated methods
KR101566368B1 (ko) 암 검출을 위한 소변 유전자 발현 비율
US20180298452A1 (en) Methods for Detection of Markers Bladder Cancer and Inflammatory Conditions of the Bladder
WO2008092094A2 (en) Method and materials for detection, diagnosis and management of ovarian cancer
CN113234830B (zh) 用于肺癌诊断的产品及用途
CA3228665A1 (en) Method of detecting adenoma
CN113981098A (zh) 用于肝癌诊断以及肝癌预后预测的生物标志物
CN113981097A (zh) 基于hspa4的生物标志物组及其在肝癌中的应用
US20240393336A1 (en) Biomarkers for colorectal cancer
CN114107504A (zh) 用于检测肺癌及肺癌预后的生物标志物
CN113943815A (zh) 基于alk的生物标志物组及其应用
CN112921094A (zh) 生物标志物用于评估早期结直肠癌
CN112795658A (zh) 早期结直肠癌的基于生物标志物的诊断
CN114015778A (zh) 预测肺癌的生物标志物组
CN112921095A (zh) 用于诊断早期结直肠癌的生物标志物及其应用
CN113025717A (zh) 早期结直肠癌的指示物
CN112921096A (zh) 早期结直肠癌的预测
CN113061657A (zh) 诊断早期结直肠癌的产品及系统
CN118556133A (zh) 子宫内膜癌的生物标记物

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ COSGROVE, LEAH JANE; TABOR, BRUCE; BURGESS, ANOTHONY WILKS AND NICE, EDOUARD COLLINS

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ COSGROVE, LEAH JANE; TABOR, BRUCE; BURGESS, ANTONY WILKS AND NICE, EDOUARD COLLINS

FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: VISION TECH BIO PTY LTD

Free format text: FORMER OWNER(S): COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION